The Patent Finder
US

Process for the Preparation of Substituted Phenylalanines

US 7,897,763 In force
OverviewFamilyAssignmentsSources & methods
Collateral for a security interest recorded Apr 4, 2023 (Antares Capital LP).

Term ends Jan 2, 2027 · Medium confidence

Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 7,855,291), so the cap could be lower.

Filed Oct 24, 2008 as application 12/257,558 · Granted Mar 1, 2011
Base term plus 5 days of patent term adjustment (USPTO delay)
Today
20 years from filing
2006 2027
Clock starts
Dec 28, 2006
Term ends
Jan 2, 2027
Granted
Mar 1, 2011
base term fee events Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
5
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,553,840, US 7,855,291, to Jan 2, 2027. The term already ends on or before that date, so the cap shortened nothing.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
3
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term runs 5 days past its 20-year base term on prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. All three maintenance fees are recorded paid; no more fees are due. Confidence: Medium. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Dec 28, 2006, when application 11/647,517, the earliest non-provisional in its chain, was filed (this one was filed Oct 24, 2008)Dec 28, 2026High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustment+5 days, USPTO patent term adjustment recordJan 2, 2027High confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 7,553,840, US 7,855,291)resolves to Jan 2, 2027, no earlier than this term, so no changeMedium confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events3 of 3 maintenance fees paidIn forceHigh confidence
Computed term endThe steps above, in orderJan 2, 2027Medium confidence

This family

US 7,855,291In force
no later than Apr 2029
no later than Apr 2029
US 7,897,763this patent
Jan 2027
Jan 2027
US 8,450,532In force
Dec 2026
Dec 2026
Every application listed has its file history here. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Jan 12, 2009
Reel 22088, frame 138
Burgoon, Hugh Alfred; Shi, Zhi-cai; Wu, Wenxue; Zhang, Haiming; Zhao, Matthew Mangzhu; Kanamarlapudi, Ramanaiah C.; Pickersgill, Iain FraserLexicon Pharmaceuticals, Inc.Assignment of Assignor's Interest
Dec 20, 2017
Reel 44958, frame 377
Lexicon Pharmaceuticals, Inc.Biopharma Credit PLCSecurity Interest
Sep 9, 2020
Reel 53721, frame 37
Tersera Therapeutics LLCNewstone Capital Partners, LLCSecurity Interest
Sep 14, 2020
Reel 53767, frame 445
Biopharma Credit PLCLexicon Pharmaceuticals, Inc.Release of Security Interest
Sep 14, 2020
Reel 53763, frame 754
Lexicon Pharmaceuticals, Inc.Tersera Therapeutics LLCAssignment of Assignor's Interest
Sep 30, 2020
Reel 53940, frame 1
Tersera Therapeutics LLCMidcap Financial Trust, As AgentSecurity Interest
Apr 4, 2023
Reel 63215, frame 724
Tersera Therapeutics LLCAntares Capital LP, as AgentSecurity Interest
Apr 4, 2023
Reel 63221, frame 546
Newstone Capital Partners, LLCTersera Therapeutics LLC; JDP Therapeutics LLCRelease of Security Interest
Apr 4, 2023
Reel 63253, frame 942
Midcap Financial Trust, As AgentTersera Therapeutics LLCRelease of Security Interest
Apr 4, 2023
reel/frame not recorded
Newstone Capital Partners, LLCTersera Therapeutics LLCRelease of Security Interest
Apr 4, 2023
reel/frame not recorded
Newstone Capital Partners, LLCJDP Therapeutics LLCRelease of Security Interest
Apr 5, 2023
Reel 63227, frame 852
Tersera Therapeutics LLCNewstone Capital Partners, LLCSecurity Interest
Jan 7, 2025
Reel 69835, frame 704
Newstone Capital Partners, LLCTersera Therapeutics LLCRelease of Intellectual Property Security Agreement Recorded at R/F 63227/0852
Apr 15, 2026
Reel 75420, frame 453
Midcap Financial TrustTersera Therapeutics LLC,Release of Intellectual Property Security Agreements at R/F 41939/0487, 46591/0544 and 53940/0001

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited